Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.63 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.50 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9741153 | 0.86 | ADORA2A (0.66) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL11596726 | 0.83 | ADORA2A (0.68) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL8466896 | 0.82 | ADORA2A (0.61) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL7832523 | 0.81 | ADORA2A (0.64) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL8467138 | 0.80 | ADORA2A (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL8464071 | 0.80 | ADORA2A (0.60) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL11596393 | 0.80 | FDPS (0.54) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL23885424 | 0.80 | P2RX7 (0.66) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL10563489 | 0.79 | FDPS (0.50) | FDPSP2RX7HDAC6FGFR1FGFR4 | |
| SCHEMBL23436498 | 0.79 | ADORA2A (0.66) | FDPSP2RX7HDAC6FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | FDPS 2071/4885P2RX7 4859/4885HDAC6 581/4885 |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | FDPS 2071/4885P2RX7 4859/4885HDAC6 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.